Metabolic medicines
Liothyronine (T3)
Synthetic T3 replacement has faster biological action than T4; hypothyroid trial findings do not establish a safe fat-loss strategy.
Small replacement trials; no healthy-user cutting evidence
Also known as: T3
Practical use
Applying the explained evidence
- Where it fits
- Synthetic T3 replacement has faster biological action than T4; hypothyroid trial findings do not establish a safe fat-loss strategy.
- Put the information into practice
- The important comparison is appropriately managed replacement in hypothyroid patients, not escalating thyroid hormone in a euthyroid athlete. Lower body weight alone does not establish better physique, preserved lean tissue or long-term safety.
- The outcome being treated
- Identify whether the evidence concerns a diagnosed condition, body weight, appetite or a laboratory marker. Check which outcomes were measured and over what follow-up before transferring a finding to another goal.
- Keep this limit in view
- The small replacement trial does not establish the composition of a healthy athlete’s weight loss or the safety of excess thyroid exposure.
Overview
Liothyronine is synthetic triiodothyronine, or T3, the active thyroid hormone. Cytomel is used for defined thyroid indications. Its US boxed warning specifically rejects use for obesity or weight loss; replacing deficiency and producing excess thyroid activity are different exposures.
Risks and limitations
Excess thyroid effect can cause arrhythmia, angina, tremor, insomnia, muscle weakness and bone loss. Uncorrected adrenal insufficiency is a contraindication. Sympathomimetics can increase toxicity; anticoagulant and diabetes-treatment effects may change. Chest pain, severe palpitations or collapse warrants urgent care.
How to read this
The important comparison is appropriately managed replacement in hypothyroid patients, not escalating thyroid hormone in a euthyroid athlete. Lower body weight alone does not establish better physique, preserved lean tissue or long-term safety.
Research explained
Metabolic comparison at similar TSH
Who was studied
14 hypothyroid patients in a randomized blinded crossover study; measured after six weeks on stable treatment at target TSH.
- Mean weight during T4 period
- 70.6 kg
- Mean weight during T3 period
- 68.5 kg
What was found
Mean weight was 70.6 kg during T4 treatment and 68.5 kg during T3 treatment. Total cholesterol fell 10.9% and LDL 13.3% relative to T4. No significant difference was detected in heart rate, blood pressure, exercise tolerance or insulin sensitivity.
What it cannot establish
Tiny, short replacement study. Failure to detect cardiovascular differences does not establish long-term safety, and the weight difference is not a fat-mass or muscle-preservation estimate.
Read the original studyPatient-centered replacement outcomes
Who was studied
75 hypothyroid patients in a randomized blinded crossover comparison of T4, T4/T3 and desiccated thyroid extract; three 22-week treatment periods.
What was found
Whole-group symptom, quality-of-life and cognitive outcomes were similar. The most symptomatic third showed preference and benefit with T3-containing treatment in subgroup analysis.
What it cannot establish
A subgroup signal is not evidence that every hypothyroid patient, or a healthy user, benefits from T3.
Read the original studyMechanism and kinetics
T3 acts through thyroid hormone receptors. Its biological half-life is about 2.5 days according to labeling, with faster onset than T4; blood-level changes and downstream tissue effects are not identical clocks.
Supporting sourceA weight difference is not a cutting prescription
The 14-person trial deliberately maintained a clinical TSH target in people who required replacement. Its 2.1 kg difference between treatment periods cannot be extrapolated to extra hormone in healthy trainees.
Supporting sourceWhat similar TSH did not settle
The metabolic study found lipid differences despite similar TSH. That suggests different tissue effects, not proof that suppressing TSH more would improve outcomes.
Supporting sourceInteraction and laboratory interpretation
Thyroid therapy has a narrow clinical target. Other medicines and assay interference can complicate interpretation; treatment response should not be judged from weight or one isolated value.
Supporting sourceReading the apparent disagreement
One study emphasizes metabolic measurements and another patient-reported/cognitive outcomes. A biochemical change can coexist with little average symptom benefit because these studies answer different questions.
Supporting sourceClaims versus findings
Not established
Lower scale weight proves T3 is a safer fat burner.
The small replacement trial does not establish the composition of a healthy athlete’s weight loss or the safety of excess thyroid exposure.
Check the evidenceCommon questions
Does T3 always improve symptoms more than T4?
No. The 75-person trial did not show overall superiority; its symptomatic-subgroup finding is more limited.
SourceSources
Cytomel prescribing information
14-patient metabolic crossover study
75-patient comparative replacement trial
Sources checked 2026-09-28.
General education; not a personal treatment plan.